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ratio during a specific period of baseline diastole, when distal resistance is lowest and stable. Because all previous studies
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hThe instantaneous wave–free ratio (iFR) is a recently
proposed index of coronary disease severity, which uses
a trans-lesional pressure ratio as a measure of functional
stenosis severity. It can be calculated using conventional
pressure guide wires and differs fundamentally from
fractional flow reserve (FFR)1 because it does not require
vasodilators such as adenosine for its calculation.
The relationship between iFR and FFR has been
extensively evaluated in more than 2,000 stenoses,1–4 and
their agreement in lesion classification ranges from 80% to
90%, depending on whether the comparison is made in
clinical populations, with predominantly intermediate
lesions, or in samples with more severe stenoses.2 When
compared with independent arbiters of stenosis severity,
iFR and FFR have demonstrated equal diagnostic agreement
Figure 1
Pressure normalization, temporal alignment, and iFR calculation using the hemodynamic console.
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Also, offline studies consistently demonstrated 0.89 to 0.90 as
the optimal iFR cutoff to match an FFR of 0.80.2,3,8
To date, however, in all iFR-FFR studies, pressure data
and iFR calculation have been processed offline in a core
laboratory, after procedural termination and appropriate
data extraction. Although necessary for any new
technology during its early development, this methodol-
ogy does not reflect the future application of iFR in
clinical practice, which will be performed by clinicians,
using appropriate software installed in hemodynamic
consoles. It is not known whether these practical aspects
could affect the performance of iFR.
In this study we explored important aspects of the
relationship between iFR and FFR, when both indices
are measured in real time by clinicians. First, using a clinical
FFR cutoff of 0.80 as a reference, we evaluated whether the
diagnostic performance and optimal cutoff of iFR are
maintained, when compared with offline studies. Second,
we extended the analysis to the original 0.75 ischemic FFR
cutoff and explored theperformanceof real-time iFR tomatch
such classification of stenoses. Finally, we aimed to validate
with real-timemeasurements the previously reported iFR-FFR
hybrid strategy, using a predefined deferral iFR cutoff ofN0.93
and a predefined treatment iFR cutoff of b0.86.9Methods
Study population
Instantaneous wave–free ratio and FFR were measured
from hemodynamic consoles in 16 centers in Europe,
Asia, and Africa. The study included 392 stenoses from
313 consecutive patients who, as part of clinicalinvestigation, required functional intracoronary assess-
ment with pressure guide wires.
Hemodynamic data collection and analysis
Cardiac catheterization was performed according to
standard practice. Unfractionated intravenous heparin
(5000 IU) and 300 to 600 μg intracoronary nitrates were
given at the start of the procedure. Acquisition of
physiological data for FFR calculation was performed
according to conventional practice10 using commercially
available FFR systems (S5i and Prestige pressure guide
wire; Volcano Corporation, San Diego, California). The
method to induce pharamacologic hyperemia varied
according to conventional clinical practice at each center.
Adenosine (or adenosine triphosphate) was used for
induction of hyperemia: in 39% of the cases, it was
administered via a central line, with doses ranging from
140 to 180 μg kg−1 min−1 (median 140 μg kg−1 min−1); in
61% of the cases, the intracoronary route was used with a
median dose of 60 μg (interquartile range 36-240 μg). Each
reported iFR value and its FFR counterpart were obtained
directly from the hardware console. Instantaneous wave–
free ratio was calculated using software embedded onto
the hemodynamic consoles, which uses proprietary iFR
algorithms acting on electrocardiogram (ECG)-gated,
time-aligned pressure traces, as previously described.1
Instantaneous wave–free ratio was automatically calculat-
ed as a ratio of distal (Pd) to proximal (Pa) coronary
pressures at the baseline iFR window. Fractional flow
reserve was automatically calculated as the ratio of whole-
cycle Pd/Pa during hyperemia. Anatomical severity of
coronary stenoses was measured using quantitative
coronary angiography.
Figure 2
Importance of ECG detection for accurate iFR measurement.
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Volume 168, Number 5Prior to iFR and FFR measurements, hemodynamic
consoles ensure that the pressure data are appropriately
calibrated. These include steps required for both FFR and
iFR calculation, such as ensuring that catheter (Pa) and
wire (Pd) pressures are equal or normalized before wire
insertion. In addition, a specific step is needed before iFR
measurement, which is the adjustment of temporal delays
between Pa and Pd signals. This essential process occurs
automatically and simultaneously with pressure normal-
ization (Figure 1). Figure 2 demonstrates the importance
of ECG identification and the reliability of iFR calculation
in sinus rhythm and atrial fibrillation.
Statistical analysis
The classification agreement (and sensitivity, specific-
ity, negative predictive value, and positive predictive
value) between iFR and FFR as well the area under the
receiver operating characteristic curves (ROCAUC) were
calculated for 2 different FFR cutoffs. First, a 0.80 clinical
FFR cutoff (as per FAME, FAME II trials, and current
clinical guidelines) was used (FFR or iFR ≤0.8 as a
reference test to define significant stenoses). For this
clinical FFR cutoff, we established a prespecified iFR
cutoff of 0.90 and evaluated whether it would also
represent the optimal cutoff by ROC analysis (defined as
the best sum of sensitivity and specificity). Second, the
diagnostic performance of iFR was evaluated for a 0.75
ischemic FFR cutoff, as per original validation studies
and DEFER11,12 (FFR or iFR ≤0.75 as a reference test to
define significant stenoses). Finally, the diagnostic
performance of iFR was explored when allowing for
the 0.75 to 0.80 FFR gray zone (zone of values which,according to DEFER and FAME/FAME II studies, is both
safe to defer and treat stenoses). Comparisons between
proportions (classification agreement between iFR and
FFR) observed in this study with previous offline data sets
were made with the χ2 test for homogeneity of
proportions. Areas under the receiver operating charac-
teristic curve were compared using the method
described by DeLong et al13 in STATA, version 11
(StataCorp, College Station, Texas). Data are expressed
as mean ± SD. A P value of b.05 was considered
statistically significant.
Hybrid iFR-FFR analysis
The real-time iFR and FFR values reported in this sample
were evaluated in a hybrid decision-making strategy,
according to the methodology previously described.9 We
aimed to prospectively apply the following decision-
making arms into this sample: when iFR N0.93, stenoses
would be deferred; when iFR b0.86, stenoses would be
treated; when iFR would fall between 0.86 and 0.93, FFR
would be calculated. For such strategy, we evaluated the
overall agreement in stenoses classification with an FFR-
only strategy and the proportion of stenoses spared from
vasodilator administration.
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Table. Demographic and angiographic data
No. of stenoses (patients) 392 (313)
Age (y), mean ± SD 67 ± 11
Male % 79
Comorbidities (%)
Hypertension 74
Hypercholesterolemia 67
Smoking history 51
Diabetes 30
Ejection fraction, mean ± SD 58 ± 12
Clinical presentation (%)
Stable angina 73
Unstable angina (nonculprit vessel) 27
Coronary anatomy (%)
Single-vessel CAD 36
Multivessel CAD 63
LAD 66
LCx 10
RCA 14
Other 10
Diameter stenosis (%), men ± SD 56 ± 13
Adenosine route (%)
Intravenous 39
Intracoronary 61
Abbreviations: CAD, Coronary artery disease; LAD, left anterior descending artery;
LCx, left circumflex artery; RCA, right coronary artery.
Figure 3
requency distribution of FFR and percentage diameter stenosis
alues in the study.
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Results
Sample characteristics
The 392 stenoses (from 313 patients) included in this
study demonstrated a unimodal distribution of FFR and
diameter stenosis values. Population demographic and
angiographic data are presented in Table. Fractional flow
reserve and iFR were measured in all attempted cases.
Mean FFR was 0.82 ± 0.10, and mean iFR was 0.89 ± 0.11.
This sample was formed predominantly by physiological-
ly intermediate lesions, with 71% of stenoses falling
between FFR 0.70 and 0.90. The proportion of stenoses
with FFR values lower than 0.80, 0.75, 0.60, and 0.50,
respectively, was 39%, 18%, 4.6%, and 1.3%. Mean
percentage diameter stenosis was 56% ± 13%, with 84%
of lesions falling within the 40% to 80% group. Figure 3
presents a histogram of FFR and diameter stenosis values.
Classification agreement between iFR and FFR
Using a clinical FFR cutoff of 0.80. In this sample,
the predefined iFR cutoff of 0.90 was also identified as the
ROC-derived optimal cutoff, yielding a classification
agreement with FFR of 80%. The ROCAUC for iFR to was
0.87 (CI 0.84-0.91). The diagnostic agreement between
iFR and FFR when measured in real time (80%) was not
different from previously reported offline studies
performed in clinical samples (RESOLVE study8 80%,F
vN = 1,593; ADVISE Registry2 study 80%, N = 339; and by
Park et al3 82%, N = 238; P = .95 for all comparisons). The
detailed diagnostic performance of iFR is summarized in
Figure 4. For this clinical FFR cutoff, the diagnostic
relationship between iFR and FFR remained
close within the intermediate anatomical lesion range
(iFR-FFR ROCAUC within 40%-80% diameter stenosis =
0.86 [0.83-0.90]).
Using a ischemic FFR cutoff of 0.75. For the
ischemic FFR cutoff, classification match between iFR
and FFR was 88% with an ROCAUC of 0.90 (CI 0.86-0.94).
To match an FFR of 0.75, the ROC-derived optimal iFR
cutoff was 0.85 (Figure 4). For this ischemic FFR cutoff,
the diagnostic relationship between iFR and FFR also
remained unchanged within the intermediate anatomical
lesion range (iFR-FFR ROCAUC within 40%-80% diameter
stenosis = 0.88 [0.85-0.91]).
Figure 4
Diagnostic agreement between iFR and FFR.
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Volume 168, Number 5When the FFR values falling into the 0.75 to 0.80 gray
zone were considered equally safe to be classified as
normal or abnormal, the ROCAUC increased to 0.93
(CI 0.90-0.96) and the classification agreement between
iFR and FFR to 92%. Both ROCAUC and classification
agreement were significantly higher when accounting for
the FFR gray zone, when compared with single FFR
cutoffs (P b .001 for comparisons against FFR 0.75
and FFR 0.80).
Hybrid iFR-FFR decision-making analysis
The previously reported iFR cutoffs of a hybrid iFR-FFR
approach9 were also validated in this real-time iFR
sample. Using a predefined deferral iFR cutoff of N0.93
and a predefined treatment iFR cutoff of b0.86 (and
measuring FFR only in those lesions with iFR between
0.86 and 0.93) would generate a 94% overall agreement
with an FFR classification of lesions, while sparing 61% of
patients from adenosine, proportions that are
not different from the previous offline report
(Petraco et al,9 N = 577; P = .92). Figure 5 summarizes
other possible iFR-FFR diagnostic strategies.Discussion
In this study, we present the results of the first clinical
application of real-time iFR measurements in patients
undergoing invasive functional assessment of intermedi-
ate coronary stenoses. We found that (1) for a clinical FFR
cutoff of 0.80, a predefined iFR value of 0.90 provides the
optimal cutoff, with a classification match of 80%, similar
to what has been reported in previous offline studies;(2) when the originally validated 0.75 ischemic FFR cutoff
is used as a reference comparison, the agreement
between iFR and FFR increases to 88% with the optimal
iFR cutoff being 0.85; (3) when accounting for the known
0.75 to 0.80 FFR gray zone, the classification match
between iFR and FFR increases to 93%; and (4)
confirming previous reports,8,9 a hybrid decision-making
strategy with iFR and FFR could spare 61% of patients
from vasodilator, while maintaining 94% overall agree-
ment with FFR classification of lesions.Real-time iFR measurement in the catheterization
laboratory is feasible
One potential limitation applicable to all studies that so
far evaluated the relationship between iFR and FFR is the
fact that all hemodynamic analyses were performed
offline. This inevitable stage in the development of a new
technology creates the theoretical possibility of expertise
bias where only operators specifically trained in the
offline analysis of hemodynamic traces, such as in a core
laboratory, perform the analysis. We have found that
when iFR is implemented in catheter laboratories around
Europe, Africa, and Asia and the measurements are
performed by clinicians who routinely perform function-
al assessment using pressure guide wires, the close
agreement between iFR and FFR is maintained. Our
results, therefore, demonstrate the feasibility of iFR use
by the clinical community and the applicability of earlier
offline core laboratory reports to clinical practice.
Figure 6 shows 2 examples of lesion interrogation by
iFR and FFR.
Figure 5
Decision-making strategies of revascularization, using iFR only (bottom panel) and a hybrid iFR-FFR approach (top panel). FFR gray zone
(0.75-0.80) refers to a region within which is known to be safe to defer and treat stenoses with equivalent clinical outcomes.
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FFR classification
In this study, when a clinical FFR cutoff of 0.80 was
used as a reference comparison, a prespecified iFR value
of 0.90 was also found to be the optimal cutoff identified
by ROC, yielding a classification agreement of 80%, with
an ROCAUC of 0.87. This comparison with an FFR of 0.80
is important because it reflects current clinical guidelines,
14 is in line with FAME15 and FAME II studies,16 and
validates with real-time measurements the results of all
previous iFR-FFR studies in clinical populations.2,3,8
Performance of iFR to identify FFR-ischemic stenoses
Despite its clinical use for decision making, it must be
remembered that FFR 0.80 is not an ischemia-derived FFR
optimal cutoff. Studies that evaluated FFR against
measures of myocardial perfusion more consistently
identified FFR 0.74 to 0.75 as the optimal FFR cutoff.11
The change from FFR 0.75 to 0.80 was subsequently
implemented in large clinical trials15,16 and was aimed to
increase the negative predictive value of FFR-based
decisions and avoid significant lesions being missed by
a lower cutoff of FFR 0.75. Therefore, the original andextensively validated ischemic 0.75 FFR cutoff12 13 is also
essential for new indices to be validated against, as it
has been shown to provide the best match to
previous perfusion modalities.11,14,15 Indeed, in ADVISE
in-practice when such a comparison was made, the
agreement between iFR and FFR increased to 88% when
an iFR cutoff of 0.85 was used. In addition, the finding of
an iFR cutoff of 0.85 being equivalent to an FFR of 0.75 is
very supportive to the ischemic iFR cutoff found in the
CLARIFY study (iFR 0.86), which used invasive flow as a
reference discriminator.5 Also, similarly to what has been
observed with FFR, a higher iFR value of N0.90 increases
the negative predictive value of iFR to 95% to exclude
ischemic stenoses (FFR ≤ 0.75).
Therefore, across studies reported so far, in more than
2,000 patients, there appears to be a consistent ischemic
iFR cutoff of 0.85 to 0.86, which matches an FFR 0.75,
and a clinical iFR cutoff of iFR 0.89 to 0.90, which
provides the best agreement with the clinically used FFR
of 0.80. Reassuringly, similar to FFR, our findings confirm
the presence of these 2 distinct iFR cutoffs (ischemic and
clinical) when measurements are performed in real time,
by interventionalists in the catheter laboratory.
Figure 6
Screenshots of measurements of iFR and FFR. A, An example of interrogation in the left circumflex artery (horizontal arrow), in which both iFR and
FFR were negative, above their respective cutoffs of 0.90 and 0.80; revascularization was deferred. B, An example in which both iFR and FFR
revealed a functionally significant stenosis in the proximal segment of the left anterior descending artery (oblique arrow); percutaneous
revascularization was performed. Because iFR is performed without the need for vasodilator administration, the time of lesion interrogation is
typically reduced to around 5 to 10 seconds, from 60 to 120 seconds for FFR.
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Volume 168, Number 5The FFR 0.75 to 0.80 gray zone: safety implications for
the development of new indices
Early studies that validated FFR as a new diagnostic
method identified optimal cutoffs that varied slightly
from 0.66, 0.72, 0.74, to 0.75.11 The validity of the 0.75
cutoff was subsequently confirmed in 2 landmark studies,
which laid the foundations of FFR as a clinical tool. First,
the multitesting study that compared FFR against
3 noninvasive functional methods17 undoubtedly dem-
onstrated that no ischemia was detected when FFR fell
between 0.75 and 0.80 and only 1 case when between
0.74 and 0.83. This safety was later translated into clinical
outcomes with the results of the DEFER study,12 which
documented a rate of major cardiac events of less than
0.6% per year for deferred stenoses with FFR values of
≥0.75.18 Recently, however, FAME and FAME II have also
demonstrated the safety and prognostic importance of
revascularizing lesions with FFR ≤0.80.15,16 Therefore,
the 0.75 to 0.80 FFR zone is a region within which it is
known to be equally safe to defer and treat stenoses,
where ischemia is almost certainly absent but cannot be
always excluded.
This DEFER-FAME gray zone not only is clinically
relevant (as it permits clinicians to defer or treat stenoseswith the same confidence)19 but also has implications to
the development of new indices, which use the safety of
FFR classification of lesions as a reference comparison.
For instance, we have found that when this gray zone is
taken into account, and either a DEFER or FAME
approach is taken, iFR classification match with FFR
increases to 92% with an ROCAUC of 0.93. This suggests
that most of iFR-FFR disagreements are unlikely to be
prognostic, as they predominantly fall in the FFR gray
zone. Future trials with clinical outcomes will need to
confirm this finding prospectively.
Hybrid approach confirms adenosine-sparing potential
of iFR application
Until clinical outcome studies judge the merits of iFR as
an independent diagnostic method, clinicians might
prefer to maintain a higher magnitude (N90%) of
classification agreement with FFR, given its established
role to select lesions for revascularization. For this
purpose, a hybrid decision-making strategy using both
iFR and FFR can be applied. A hybrid analysis on this real-
time iFR data set with prespecified cutoffs has repro-
duced the results reported previously.9 Our findings
confirm the potential feasibility of using iFR and FFR
Figure 7
The FLAIR trial will evaluate the clinical merits of iFR guided revascularization.
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61% of patients could be spared from vasodilator, while
maintaining the safety of a 94% match with FFR
classification of lesions (Figure 5).Study samples of patients undergoing invasive
physiological assessment in clinical practice: how do
they differ from large randomized clinical trials?
The present study also highlights an important feature
of unselected clinical FFR cohorts: they are predominant-
ly formed by intermediate FFR values. In the present
sample, mean FFR was 0.82 ± 0.10, with 71% of stenoses
falling within the 0.70 and 0.90 FFR range and only 20%
≤0.75 and 39% ≤0.80. Importantly, physiologically
severe lesions appear extremely rare in samples in
which FFR is used to guide clinical decisions, with only
4.6% having an FFR≤0.6 and 1.3%≤0.5. These figures are
very similar to what has been previously reported in large
independent clinical cohorts from Europe2 and Asia3 and
reflect routine clinical application of FFR as recommend-
ed per guidelines.14 Importantly, they differ markedly
from the distribution of FFR values of previous large FFR
clinical trials. For instance, mean FFR of treated lesions in
DEFER12 was 0.57 ± 0.16, while in FAME,15 it was 0.60 ±
0.14. Notably, in the medical arm of FAME II study,16 19%
and 26% of the stenoses had FFR less than 0.50 and 0.60,respectively, which contrasts with the rarity of such
severe lesions in clinical samples.
These differences between unselected clinical cohorts
and studies in which patients are actively recruited by
investigators are very relevant. First, they demonstrate that
interventionalists have an excellent overall clinical judge-
ment as towhich stenoses require functional interrogation,
as most clinically selected anatomically intermediate
stenoses are also physiologically intermediate (Figure 3).
Second, it appears that clinical populations such as found in
this study provide the most conservative scenario with
respect to the magnitude of agreement between iFR and
FFR, because they are predominantly formed by interme-
diate FFR values, when disagreements are naturally
higher.2,20 In populations with more severe lesions, such
as in DEFER or FAME studies, classification agreement
between iFR and a clinical FFR cutoff of 0.80 is expected to
be higher, around 90%, as previously demonstrated.1,21
Clinical implications of our findings
Routine clinical application of a vasodilator-free index
such as iFR could potentially expand the benefits of
physiology-guided revascularization to many more
patients with coronary disease, as the need for vasodilator
is one of the reasons for the low adoption of FFR.22 In
South Africa, for example, 15 ampoules of a specific
adenosine preparation are required for one intravenous
Petraco et al 747
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Volume 168, Number 5infusion, at considerable cost. Similar restrictions occur in
other countries, such as Russia, Turkey, and in Latin
America, where papaverine is still frequently used as a
hyperemic agent with its incumbent risks of serious
cardiac arrhythmias.23 The costs and procedural delays
associated with vasodilator administration (particularly
long intravenous infusions, the recommended route for a
complete vessel assessment) are particularly relevant
to patients with multivessel disease, who might need 3-
vessel interrogation. This group of patients is perhaps the
one that benefits the most from invasive evaluation of
intermediate stenoses,15,16 although it appears to be the
most affected by the lack of its widespread adoption.
Future directions: the need for clinical trials
An accumulation of evidence supports iFR as an index of
stenosis severity. However, clinical outcome data are
required to further advance the global adoption of iFR as a
single measure in clinical decision making. The DEFINE-
FLAIR trial (NCT 02053038) will compare strategies of
revascularization guided by iFR and FFR in 2,500 patients
requiring physiological interrogation in clinical practice.
The primary outcome will be the rate of major adverse
cardiac events (composite of death,myocardial infarction,
and unplanned revascularization) at 1 year (Figure 7).
Other studies, such as the SYNTAX II, Prospect II, and iFR-
SWEDEHEART will further evaluate the merits of iFR in
clinical decision making.
Limitations
The present study only performed a direct comparison
between the classification of stenoses by iFR and FFR. No
alternative noninvasive method was applied in this
analysis, which prevents a more in-depth interpretation
of iFR-FFR disagreements.
There was no active recruitment of study subjects.
Patients included in this study represent the selection of
clinicians based on a clinical indication for FFR measure-
ment. Also, no formal measurement protocol for iFR or
FFR was suggested, and technical aspects were left to the
discretion of the interventionalist according to their
routine clinical practice. Also, iFR and FFR measurements
were not blinded from each other, as the clinical operator
had access to both results.
Although each individual FFR value might have been
different if different doses or routes of adenosine were
used, it is likely that on average, across the whole study
population, this would not affect the overall relationship
with iFR because this variability would likely occur in
both ways (more or less hyperemia). Importantly, as a
retrospective analysis of the routine clinical application of
FFR, our study used no fixed protocol of adenosine
administration, which means that our results entirely
reflect the choice of clinicians and the way FFR is used
everyday around the world. This can be seen as a strengthof our study because the relationship between iFR and
FFR, therefore, reflects the clinical relationship expected
when iFR is used for clinical reasons. Also, the recently
presented ADVISE II study,24 which used a rigid protocol
of central IV adenosine administration, demonstrated a
level of agreement between iFR and FFR equal to our
study, which again confirms the validity of our findings.
Finally, the present study cannot evaluate the impact of
iFR use on clinical outcomes because we simply
described its diagnostic agreement with FFR in clinical
practice. This merit will be addressed by the DEFINE-
FLAIR study (Figure 7) and other future trials.Conclusion
Real-time iFR measurement in the cardiac catheteriza-
tion laboratory is feasible and accessible to clinicians,
delivering the same magnitude of agreement between iFR
and FFR as described in core laboratory studies. Outcome
studies are needed to evaluate the clinical value of iFR as
an independent decision-making tool in such population.Disclosures
J.E. Davies holds patents pertaining to iFR technology,
which is under licence to Volcano Corporation. J.E. Davies
is a consultant for Volcano Corporation. The other authors
have no conflicts of interest to declare.References
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